para-aminosalicylic acid

Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

Related to para-aminosalicylic acid: Sodium aminosalicylate

par·a-a·mi·no·sal·i·cyl·ic acid

(păr′ə-ə-mē′nō-săl′ĭ-sĭl′ĭk, ăm′ə-nō-)

n. Abbr. PAS

A bacteriostatic agent, C₇H₇NO₃, prescribed for the treatment of tuberculosis. Also called aminosalicylic acid.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

Mentioned in ?

References in periodicals archive ?

The most commonly used drugs were an injectable (n = 27), a fluoroquinolone (n = 26), cycloserine/terizidone (n = 27), ethionamide/prothionamide (n = 24), and para-aminosalicylic acid (n = 25).

Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis

Twenty years afterward: historical notes on the discovery of the antituberculosis effect of para-aminosalicylic acid (PAS) and the first clinical trials.

Drug Resistant Tuberculosis: Pattern Seen among Patients Visiting Mayo Hospital, Lahore

Patients with second-line drug resistance, toxicity, or contraindications to the standardised regimen can access individualised regimens including capreomycin, para-aminosalicylic acid, clofazimine, linezolid and bedaquiline.

A call to action: addressing the reproductive health needs of women with drug-resistant tuberculosis

We have developed a nanodelivery formulation based on para-aminosalicylic acid (PAS) and zinc layered hydroxide using zinc nitrate salt as a precursor.

Development of a highly biocompatible antituberculosis nanodelivery formulation based on para-aminosalicylic acid--zinc layered hydroxide nanocomposites

* Given the high background rates of TB and MDR-TB in several countries, regimens are often constructed around a backbone of capreomycin and para-aminosalicylic acid

Drug-resistant tuberculosis

It was reported yesterday that the contract has been signed to produce Para-Aminosalicylic Acid to be marketed and distributed by Advance Trading.

Rafarma signs contract with Advance Trading

Rhee's research team exposed TB to para-aminosalicylic acid (PAS), which was developed more than 50 years ago, and is still part of the multi-drug regimen used to treat resistant TB.

Mass spectrometry lets scientists see how antibiotics attack TB bacteria inside cells

This started with non-pharmacological methods to the discovery of effective medications (streptomycin and para-aminosalicylic acid) in 1944; the development of "triple therapy" (streptomycin, para-aminosalicylic acid and isoniazid) in 1952, assured cure.